Synthetic Growth Hormone-Releasing Peptides (GHRPs): A Historical Appraisal of the Evidences Supporting Their Cytoprotective Effects
暂无分享,去创建一个
J. Berlanga-Acosta | F. Hernández-Bernal | Y. Mendoza-Marí | Ariana García-Ojalvo | G. Guillén-Nieto | Arielis Rodríguez-Ulloa | Angel Abreu-Cruz | Diana García-del Barco Herrera | Viviana Falcón‐Cama | Qu Beichen | Viviana Falcón-Cama | Beichen Qu
[1] Jorge Berlanga Acosta,et al. Growth Hormone-Releasing Peptide 6 Enhances the Healing Process and Improves the Esthetic Outcome of the Wounds , 2016, Plastic surgery international.
[2] C. Gibson,et al. Assessment of dose–effect and therapeutic time window in preclinical studies of rhEGF and GHRP-6 coadministration for stroke therapy , 2016, Neurological research.
[3] Bong-Woo Kim,et al. Growth hormone-releasing peptide-biotin conjugate stimulates myocytes differentiation through insulin-like growth factor-1 and collagen type I , 2015, BMB reports.
[4] Alan R. Harvey,et al. The Acquisition of Target Dependence by Developing Rat Retinal Ganglion Cells , 2015, eNeuro.
[5] A. Abizaid,et al. Growth Hormone Secretagogue Receptor Dimers: A New Pharmacological Target1,2,3 , 2015, eNeuro.
[6] Zhen Zhang,et al. Implications of ghrelin and hexarelin in diabetes and diabetes-associated heart diseases , 2015, Endocrine.
[7] Yuanfeng Xia,et al. Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile , 2014, Journal of cachexia, sarcopenia and muscle.
[8] T. Tokudome,et al. The cardiovascular action of hexarelin , 2014, Journal of geriatric cardiology : JGC.
[9] P. Saura,et al. Seguridad clínica del péptido liberador de la hormona de crecimiento-6 (GHRP-6) en voluntarios sanos , 2014 .
[10] P. Simkhada,et al. Cardioprotective Effects of Ghrelin in Heart Failure: From Gut to Heart , 2014, Heart views : the official journal of the Gulf Heart Association.
[11] Jorge Amador Berlanga Acosta,et al. Role of epidermal growth factor and growth hormone-releasing peptide-6 in acceleration of renal tissue repair after kanamycin overdosing in rats , 2014 .
[12] H. Szeto. First‐in‐class cardiolipin‐protective compound as a therapeutic agent to restore mitochondrial bioenergetics , 2014, British journal of pharmacology.
[13] P. Loria,et al. Discovery of PF-5190457, a Potent, Selective, and Orally Bioavailable Ghrelin Receptor Inverse Agonist Clinical Candidate. , 2014, ACS medicinal chemistry letters.
[14] N. Minamino,et al. Hexarelin treatment in male ghrelin knockout mice after myocardial infarction. , 2013, Endocrinology.
[15] Shiqiang Yu,et al. Cardioprotective Effect of Ghrelin in Cardiopulmonary Bypass Involves a Reduction in Inflammatory Response , 2013, PloS one.
[16] E. Braunwald. Cardiovascular science: opportunities for translating research into improved care. , 2013, The Journal of clinical investigation.
[17] Ji-min Cao,et al. Chronic administration of hexarelin attenuates cardiac fibrosis in the spontaneously hypertensive rat. , 2012, American journal of physiology. Heart and circulatory physiology.
[18] B. Launikonis,et al. Growth hormone secretagogues preserve the electrophysiological properties of mouse cardiomyocytes isolated from in vitro ischemia/reperfusion heart. , 2012, Endocrinology.
[19] Ji-min Cao,et al. Gastric mucosal damage in water immersion stress: mechanism and prevention with GHRP-6. , 2012, World journal of gastroenterology.
[20] M. Ochagavía,et al. Growth Hormone Releasing Peptide 6 (GHRP6) reduces liver fibrosis in CCl4 chronically intoxicated rats , 2012 .
[21] B. Launikonis,et al. Growth Hormone Secretagogues Protect Mouse Cardiomyocytes from in vitro Ischemia/Reperfusion Injury through Regulation of Intracellular Calcium , 2012, PloS one.
[22] E. Braunwald. Clinical Efforts to Reduce Myocardial Infarct Size—The Next Step , 2011, Journal of cardiovascular pharmacology and therapeutics.
[23] W. Zang,et al. Effects of GH secretagogues on contractility and Ca2+ homeostasis of isolated adult rat ventricular myocytes. , 2010, Endocrinology.
[24] Chao-shu Tang,et al. Ghrelin and Cardiovascular Diseases , 2009, Current Cardiology Reviews.
[25] P. Delafontaine,et al. Growth hormone-releasing peptide-2 suppresses vascular oxidative stress in ApoE-/- mice but does not reduce atherosclerosis. , 2009, Endocrinology.
[26] A. Asakawa,et al. Growth hormone releasing peptide 2 reverses anorexia associated with chemotherapy with 5-fluoruracil in colon cancer cell-bearing mice. , 2008, World journal of gastroenterology.
[27] K. Chihara,et al. GHRP-2, a GHS-R agonist, directly acts on myocytes to attenuate the dexamethasone-induced expressions of muscle-specific ubiquitin ligases, Atrogin-1 and MuRF1. , 2008, Life sciences.
[28] S. Grottoli,et al. Growth hormone levels in the diagnosis of growth hormone deficiency in adulthood , 2007, Pituitary.
[29] A. Rodrigue-Way,et al. A growth hormone-releasing peptide promotes mitochondrial biogenesis and a fat burning-like phenotype through scavenger receptor CD36 in white adipocytes. , 2007, Endocrinology.
[30] J. S. Alba,et al. Growth-hormone-releasing peptide 6 (GHRP6) prevents oxidant cytotoxicity and reduces myocardial necrosis in a model of acute myocardial infarction. , 2007, Clinical science.
[31] R. Playford,et al. Use of growth-hormone-releasing peptide-6 (GHRP-6) for the prevention of multiple organ failure. , 2006, Clinical science.
[32] M. Granado,et al. Anti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats. , 2005, American journal of physiology. Endocrinology and metabolism.
[33] R. Silverstein,et al. Identification of the growth hormone-releasing peptide binding site in CD36: a photoaffinity cross-linking study. , 2004, The Biochemical journal.
[34] R. Bolli,et al. Myocardial Protection at a Crossroads: The Need for Translation Into Clinical Therapy , 2004, Circulation research.
[35] Ji-min Cao,et al. The positive inotropic and calcium-mobilizing effects of growth hormone-releasing peptides on rat heart. , 2003, Endocrinology.
[36] R. Hargreaves,et al. A Growth Hormone Secretagogue Prevents Ischemic-Induced Mortality Independently of the Growth Hormone Pathway in Dogs with Chronic Dilated Cardiomyopathy , 2003, Journal of Pharmacology and Experimental Therapeutics.
[37] C. Ohlsson,et al. Natural (ghrelin) and synthetic (hexarelin) GH secretagogues stimulate H9c2 cardiomyocyte cell proliferation. , 2002, The Journal of endocrinology.
[38] E. Ghigo,et al. Effects of acute hexarelin administration on cardiac performance in patients with coronary artery disease during by-pass surgery. , 2002, European journal of pharmacology.
[39] R. Silverstein,et al. CD36 Mediates the Cardiovascular Action of Growth Hormone-Releasing Peptides in the Heart , 2002, Circulation research.
[40] M. Root,et al. Clinical pharmacology of human growth hormone and its secretagogues. , 2002, Current drug targets. Immune, endocrine and metabolic disorders.
[41] E. Arvat,et al. Growth hormone-independent cardiotropic activities of growth hormone-releasing peptides in normal subjects, in patients with growth hormone deficiency, and in patients with idiopathic or ischemic dilated cardiomyopathy , 2001, Endocrine.
[42] M. Papotti,et al. Growth hormone-releasing peptides and the cardiovascular system. , 2000, Annales d'endocrinologie.
[43] M. Nakazato,et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach , 1999, Nature.
[44] E. Ghigo,et al. Cardiac effects of hexarelin in hypopituitary adults. , 1999, European journal of pharmacology.
[45] M. Morello,et al. Activity of GH/IGF‐I axis in patients with dilated cardiomyopathy , 1999, Journal of endocrinological investigation.
[46] C. Bowers,et al. Growth hormone-releasing peptide (GHRP) , 1998, Cellular and Molecular Life Sciences CMLS.
[47] M. Bernareggi,et al. Protectant activity of hexarelin or growth hormone against postischemic ventricular dysfunction in hearts from aged rats. , 1998, Journal of cardiovascular pharmacology.
[48] M. Bernareggi,et al. Cardiac ischemia and impairment of vascular endothelium function in hearts from GH-deficient rats: Protection by hexarelin , 1997 .
[49] F. Momany,et al. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. , 1984, Endocrinology.
[50] Diana García del Barco Herrera,et al. Role of epidermal growth factor and growth hormone-releasing peptide-6 in acceleration of renal tissue repair after kanamycin overdosing in rats. , 2014, Iranian journal of kidney diseases.
[51] Jorge Amador Berlanga Acosta,et al. Epidermal growth factor and growth hormone-releasing peptide-6: combined therapeutic approach in experimental stroke. , 2013, Restorative neurology and neuroscience.
[52] L. Silengo,et al. Cardiotropic effect of GHRP-6 : in vivo characterization by echocardiography , 2013 .
[53] T. Tokudome,et al. Ghrelin and cardiovascular diseases. , 2012, Journal of cardiology.
[54] E. Montero,et al. Coadministration of epidermal growth factor and growth hormone releasing peptide-6 improves clinical recovery in experimental autoimmune encephalitis. , 2011, Restorative neurology and neuroscience.
[55] K. Nagata,et al. Beneficial effects of growth hormone-releasing peptide on myocardial oxidative stress and left ventricular dysfunction in dilated cardiomyopathic hamsters. , 2010, Circulation journal : official journal of the Japanese Circulation Society.
[56] D. Cibrian,et al. Therapeutic Effect of the Combined Use of Growth Hormone Releasing Peptide-6 and Epidermal Growth Factor in an Axonopathy Model , 2010, Neurotoxicity Research.
[57] M. Granado,et al. GH-releasing peptide-2 administration prevents liver inflammatory response in endotoxemia. , 2008, American journal of physiology. Endocrinology and metabolism.
[58] J. Suárez,et al. Efecto citoprotector cardíaco y extracardíaco del péptido GHRP6 , 2008 .
[59] D. Lamontagne,et al. Cardiac and peripheral actions of growth hormone and its releasing peptides: relevance for the treatment of cardiomyopathies. , 2006, Cardiovascular research.
[60] H. Izawa,et al. Growth hormone-releasing peptide can improve left ventricular dysfunction and attenuate dilation in dilated cardiomyopathic hamsters. , 2004, Cardiovascular research.
[61] E. Arvat,et al. Natural and Synthetic Growth Hormone Secretagogues , 2003, Treatments in endocrinology.
[62] G. Van den Berghe,et al. Pretreatment with growth hormone-releasing peptide-2 directly protects against the diastolic dysfunction of myocardial stunning in an isolated, blood-perfused rabbit heart model. , 2000, Endocrinology.
[63] M. Bernareggi,et al. Cardiac ischemia and impairment of vascular endothelium function in hearts from growth hormone-deficient rats: protection by hexarelin. , 1997, European journal of pharmacology.
[64] M. Bernareggi,et al. Printed in U.S.A. Copyright © 1999 by The Endocrine Society Growth Hormone-Independent Cardioprotective Effects of Hexarelin in the Rat* , 2022 .